Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (referred to in the metadata as Phio Pharmaceuticals Corp.) on December 17, 2014. The report details two material definitive agreements entered into on December 17 and December 18, 2014: an asset acquisition from Hapten Pharmaceuticals, LLC and a new equity financing arrangement with Lincoln Park Capital Fund, LLC (LPC).
Key Financial Metrics and Agreements
- Asset Acquisition: Entered into an Assignment and Exclusive License Agreement to acquire patent rights, an investigational new drug application, and clinical data for Samcyprone gel products. Consideration includes an upfront payment (cash and stock), future milestone payments, and escalating royalties.
- Equity Financing: Entered into a Purchase Agreement with LPC allowing the sale of up to $10,800,000 in common stock. Sales are capped at $750,000 per purchase date, with a term extending to April 17, 2017.
- Commitment Fee: Issued 100,000 shares of common stock to LPC as a commitment fee for the new Purchase Agreement (no cash proceeds received).
- Use of Proceeds: Intended for working capital, funding development programs (including Samcyprone, dermatology, and ocular programs), and general corporate purposes.
Material Changes Versus Prior Period
- Termination of Prior Agreement: Terminated a previous Purchase Agreement with LPC dated April 22, 2014, which allowed for up to $20,000,000 in sales. Under the prior agreement, the company sold $2,000,000 in stock and issued 100,000 shares as a commitment fee. The remaining $18,000,000 unsold balance was terminated.
- Portfolio Expansion: Acquired the Samcyprone product candidates, expanding the company's pipeline to include treatments for alopecia areata, warts, and cutaneous metastases of malignant melanoma.
Guidance, Outlook, and Risks
- Development Timeline: The company intends to complete ongoing Phase 2a studies for Samcyprone and initiate Phase 2b studies in 2016.
- Closing Conditions: The acquisition of Samcyprone assets is subject to closing conditions and is scheduled to occur no later than February 2015.
- Forward-Looking Risks: Risks include the timeliness of the asset acquisition closing, the success of development plans, and market conditions affecting the ability to sell shares under the new Purchase Agreement.
- Financial Metrics: The filing text does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Investor Verification Checklist
- Verify the closing date and satisfaction of conditions for the Hapten Pharmaceuticals asset acquisition.
- Monitor the actual volume and pricing of shares sold under the new $10.8 million Purchase Agreement with LPC.
- Review the progress of Phase 2a trials for Samcyprone in viral warts, melanoma, and alopecia areata.
- Confirm the dilution impact of the 100,000 commitment fee shares and potential future milestone payments.